Evaluation of cardiovascular biomarkers In HIV-infected patients switching to abacavir or tenofovir based therapy

BMC Infectious Diseases

Volumn 11, Issue , 2011, Pages

  Rasmussen, Thomas A ^a   Tolstrup, Martin ^a   Melchjorsen, Jesper ^a   Frederiksen, Christian A ^a   Nielsen, Ulla S ^a   Langdahl, Bente L ^a   Østergaard, Lars ^a   Laursen, Alex L ^a  

^a AARHUS UNIVERSITY HOSPITAL   (Denmark)

Author keywords

Abacavir; Cardiovascular disease; Hiv; Tenofovir

Indexed keywords

ABACAVIR PLUS LAMIVUDINE; BIOLOGICAL MARKER; C REACTIVE PROTEIN; D DIMER; EMTRICITABINE PLUS TENOFOVIR DISOPROXIL; ENDOTHELIAL LEUKOCYTE ADHESION MOLECULE 1; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; INTERCELLULAR ADHESION MOLECULE 1; INTERLEUKIN 6; LAMIVUDINE PLUS ZIDOVUDINE; MYELOPEROXIDASE; VASCULAR CELL ADHESION MOLECULE 1; VIRUS RNA; 2',3' DIDEOXYNUCLEOSIDE DERIVATIVE; ABACAVIR; ADENINE; ANTI HUMAN IMMUNODEFICIENCY VIRUS AGENT; DEOXYCYTIDINE; DRUG DERIVATIVE; EMTRICITABINE; LAMIVUDINE; PHOSPHONIC ACID DERIVATIVE; TENOFOVIR;

ADULT; ARTICLE; CARDIOVASCULAR RISK; CHOLESTEROL BLOOD LEVEL; CLINICAL ARTICLE; CONTROLLED STUDY; DRUG SAFETY; DRUG SUBSTITUTION; DRUG TOLERABILITY; DRUG WITHDRAWAL; ENDOTHELIAL DYSFUNCTION; FEMALE; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; MALE; OPEN STUDY; PARALLEL DESIGN; PROTEIN BLOOD LEVEL; RANDOMIZED CONTROLLED TRIAL; SIDE EFFECT; BLOOD; CARDIOVASCULAR DISEASE; CHEMISTRY; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; METHODOLOGY; MIDDLE AGED; PATHOPHYSIOLOGY; PLASMA;

ADENINE; ADULT; ANTI-HIV AGENTS; ANTIRETROVIRAL THERAPY, HIGHLY ACTIVE; BIOLOGICAL MARKERS; CARDIOVASCULAR DISEASES; DEOXYCYTIDINE; DIDEOXYNUCLEOSIDES; E-SELECTIN; FEMALE; HIV INFECTIONS; HUMANS; LAMIVUDINE; MALE; MIDDLE AGED; PHOSPHONIC ACIDS; PLASMA; VASCULAR CELL ADHESION MOLECULE-1;

EID: 80053466145     PISSN: None     EISSN: 14712334     Source Type: Journal    
DOI: 10.1186/1471-2334-11-267     Document Type: Article

References (30)

1. Sabin CA, Worm SW, Weber R, Reiss P, El-Sadr W, Dabis F, De WS, Law M, D'Arminio MA, Friis-Moller N, Kirk O, Pradier C, Weller I, Phillips AN, Lundgren JD. Use of nucleoside reverse transcriptase inhibitors and risk of myocardial infarction in HIV-infected patients enrolled in the D:A:D study: a multi-cohort collaboration. Lancet 2008, 371(9622):1417-1426. 2688660, 18387667.
2. Ribaudo HJ, Benson CA, Zheng Y, Koletar SL, Collier AC, Lok JJ, Smurzynski M, Bosch RJ, Bastow B, Schouten JT. No risk of myocardial infarction associated with initial antiretroviral treatment containing abacavir: short and long-term results from ACTG A5001/ALLRT. Clin Infect Dis 2011, 52(7):929-940. 10.1093/cid/ciq244, 21427402.
3. Bedimo RJ, Westfall AO, Drechsler H, Vidiella G, Tebas P. Abacavir use and risk of acute myocardial infarction and cerebrovascular events in the highly active antiretroviral therapy era. Clin Infect Dis 2011, 53(1):84-91. 10.1093/cid/cir269, 21653308.
4. Obel N, Farkas DK, Kronborg G, Larsen CS, Pedersen G, Riis A, Pedersen C, Gerstoft J, Sorensen HT. Abacavir and risk of myocardial infarction in HIV-infected patients on highly active antiretroviral therapy: a population-based nationwide cohort study. HIVMed 2010, 11(2):130-136.
5. Lang S, Mary-Krause M, Cotte L, Gilquin J, Partisani M, Simon A, Boccara F, Costagliola D. Impact of individual antiretroviral drugs on the risk of myocardial infarction in human immunodeficiency virus-infected patients: a case-control study nested within the French Hospital Database on HIV ANRS cohort CO4. Arch Intern Med 2010, 170(14):1228-1238. 10.1001/archinternmed.2010.197, 20660842.
6. Brothers CH, Hernandez JE, Cutrell AG, Curtis L, Ait-Khaled M, Bowlin SJ, Hughes SH, Yeo JM, Lapierre DH. Risk of myocardial infarction and abacavir therapy: no increased risk across 52 GlaxoSmithKline-sponsored clinical trials in adult subjects. JAcquirImmuneDeficSyndr 2009, 51(1):20-28.
7. Use of nucleoside reverse transcriptase inhibitors and risk of myocardial infarction in HIV-infected patients. AIDS 2008, 22(14):F17-F24. 2644883, 18753925.
8. Martin A, Bloch M, Amin J, Baker D, Cooper DA, Emery S, Carr A. Simplification of antiretroviral therapy with tenofovir-emtricitabine or abacavir-Lamivudine: a randomized, 96-week trial. ClinInfectDis 2009, 49(10):1591-1601.
9. Martinez E, Arranz JA, Podzamczer D, Lonca M, Sanz J, Barragan P, Ribera E, Knobel H, Roca V, Gutierrez F, Blanco JL, Mallolas J, Llibre JM, Clotet B, Dalmau D, Segura F, Arribas JR, Cosin J, Barrufet P, Casas E, Ferrer E, Curran A, Gonzalez A, Pich J, Cruceta A, Arnaiz JA, Miro JM, Gatell JM. A simplification trial switching from nucleoside reverse transcriptase inhibitors to once-daily fixed-dose abacavir/lamivudine or tenofovir/emtricitabine in HIV-1-infected patients with virological suppression. JAcquirImmuneDeficSyndr 2009, 51(3):290-297.
10. Sax PE, Tierney C, Collier AC, Fischl MA, Mollan K, Peeples L, Godfrey C, Jahed NC, Myers L, Katzenstein D, Farajallah A, Rooney JF, Ha B, Woodward WC, Koletar SL, Johnson VA, Geiseler PJ, Daar ES. Abacavir-lamivudine versus tenofovir-emtricitabine for initial HIV-1 therapy. NEnglJMed 2009, 361(23):2230-2240.
11. Smith KY, Patel P, Fine D, Bellos N, Sloan L, Lackey P, Kumar PN, Sutherland-Phillips DH, Vavro C, Yau L, Wannamaker P, Shaefer MS. Randomized, double-blind, placebo-matched, multicenter trial of abacavir/lamivudine or tenofovir/emtricitabine with lopinavir/ritonavir for initial HIV treatment. AIDS 2009, 23(12):1547-1556. 10.1097/QAD.0b013e32832cbcc2, 19542866.
12. Ding XA-CE, Cooper C, Miele P, Kornegay C, Soukup M, Marcus K. No Association of Myocardial Infarction with Abacavir Use. 18th Conference on Retroviruses and Opportunistic Infections 2011, Boston, Abstract # O-1004.
13. Danesh J, Kaptoge S, Mann AG, Sarwar N, Wood A, Angleman SB, Wensley F, Higgins JP, Lennon L, Eiriksdottir G, Rumley A, Whincup PH, Lowe GD, Gudnason V. Long-term interleukin-6 levels and subsequent risk of coronary heart disease: two new prospective studies and a systematic review. PLoSMed 2008, 5(4):e78.
14. Danesh J, Wheeler JG, Hirschfield GM, Eda S, Eiriksdottir G, Rumley A, Lowe GD, Pepys MB, Gudnason V. C-reactive protein and other circulating markers of inflammation in the prediction of coronary heart disease. NEnglJMed 2004, 350(14):1387-1397.
15. Ridker PM, Hennekens CH, Buring JE, Rifai N. C-reactive protein and other markers of inflammation in the prediction of cardiovascular disease in women. NEnglJMed 2000, 342(12):836-843.
16. Hammond E, McKinnon E, Mallal S, Nolan D. Longitudinal evaluation of cardiovascular disease-associated biomarkers in relation to abacavir therapy. AIDS 2008, 22(18):2540-2543. 10.1097/QAD.0b013e328319807f, 19005279.
17. Jong E, Meijers JC, van Gorp EC, Spek CA, Mulder JW. Markers of inflammation and coagulation indicate a prothrombotic state in HIV-infected patients with long-term use of antiretroviral therapy with or without abacavir. AIDS ResTher 2010, 7:9.
18. Martinez E, Larrousse M, Podzamczer D, Perez I, Gutierrez F, Lonca M, Barragan P, Deulofeu R, Casamitjana R, Mallolas J, Pich J, Gatell JM. Abacavir-based therapy does not affect biological mechanisms associated with cardiovascular dysfunction. AIDS 2010, 24(3):F1-F9. 10.1097/QAD.0b013e32833562c5, 20009917.
19. Kristoffersen US, Kofoed K, Kronborg G, Benfield T, Kjaer A, Lebech AM. Changes in biomarkers of cardiovascular risk after a switch to abacavir in HIV-1-infected individuals receiving combination antiretroviral therapy. HIVMed 2009, 10(10):627-633.
20. Humphries A, Amin J, Cooper D, Carr A, Kelleher A, Bloch M. Changes in Cardiovascular Biomarkers with Abacavir: A Randomized, 96-week trial. Paper #718, 17th Conference on Retroviruses and Oppertunistic Infections 2010, San Francisco, USA.
21. Wilson PW, D'Agostino RB, Levy D, Belanger AM, Silbershatz H, Kannel WB. Prediction of coronary heart disease using risk factor categories. Circulation 1998, 97(18):1837-1847.
22. Pearson TA, Bazzarre TL, Daniels SR, Fair JM, Fortmann SP, Franklin BA, Goldstein LB, Hong Y, Mensah GA, Sallis JF, Smith S, Stone NJ, Taubert KA. American Heart Association guide for improving cardiovascular health at the community level: a statement for public health practitioners, healthcare providers, and health policy makers from the American Heart Association Expert Panel on Population and Prevention Science. Circulation 2003, 107(4):645-651. 10.1161/01.CIR.0000054482.38437.13, 12566381.
23. Sabatine MS, Morrow DA, Jablonski KA, Rice MM, Warnica JW, Domanski MJ, Hsia J, Gersh BJ, Rifai N, Ridker PM, Pfeffer MA, Braunwald E. Prognostic significance of the Centers for Disease Control/American Heart Association high-sensitivity C-reactive protein cut points for cardiovascular and other outcomes in patients with stable coronary artery disease. Circulation 2007, 115(12):1528-1536. 10.1161/CIRCULATIONAHA.106.649939, 17372173.
24. Padilla S, Masia M, Garcia N, Jarrin I, Tormo C, Gutierrez F. Early changes in inflammatory and pro-thrombotic biomarkers in patients initiating antiretroviral therapy with abacavir or tenofovir. BMC Infect Dis 2011, 11(1):40. 10.1186/1471-2334-11-40, 3042932, 21294867.
25. De PC, Orden S, Apostolova N, Blanquer A, Esplugues JV, Alvarez A. Abacavir and didanosine induce the interaction between human leukocytes and endothelial cells through Mac-1 upregulation. AIDS 2010, 24(9):1259-1266.
26. Mulvihill NT, Foley JB, Murphy R, Crean P, Walsh M. Evidence of prolonged inflammation in unstable angina and non-Q wave myocardial infarction. JAmCollCardiol 2000, 36(4):1210-1216.
27. Blankenberg S, Rupprecht HJ, Bickel C, Peetz D, Hafner G, Tiret L, Meyer J. Circulating cell adhesion molecules and death in patients with coronary artery disease. Circulation 2001, 104(12):1336-1342. 10.1161/hc3701.095949, 11560847.
28. Blankenberg S, Barbaux S, Tiret L. Adhesion molecules and atherosclerosis. Atherosclerosis 2003, 170(2):191-203. 10.1016/S0021-9150(03)00097-2, 14612198.
29. Hwang SJ, Ballantyne CM, Sharrett AR, Smith LC, Davis CE, Gotto AM, Boerwinkle E. Circulating adhesion molecules VCAM-1, ICAM-1, and E-selectin in carotid atherosclerosis and incident coronary heart disease cases: the Atherosclerosis Risk In Communities (ARIC) study. Circulation 1997, 96(12):4219-4225.
30. Melchjorsen J, Risor MW, Sogaard OS, O'Loughlin K L, Chow S, Paludan SR, Ellermann-Eriksen S, Hedley DW, Phd HM, Ostergaard L, Phd MT. Tenofovir selectively regulates production of inflammatory cytokines and shifts the IL-12/IL-10 balance in human primary cells. J Acquir Immune Defic Syndr 2011,